Thymosin alpha-1[Zadaxin]
Compound snapshot
Class
Immune-modulating peptide
FDA approved
No in the United States; approved in several other countries
Clinical development
Phase 3
Last reviewed
September 2026
Research areas
Immune signalling / Inflammation / Longevity research
Regulatory status
FDA-approved medicine (outside the US in ~35 countries)
Internet attention
Moderate
Registry query
Thymosin alpha-1
A 28-amino-acid peptide produced by the thymus, approved in many countries for hepatitis B and C and used as an immune adjuvant.
Reality check — what we actually know
Supported by human evidence
- This compound has completed human trials in at least one approved indication — see the regulatory section for what was actually approved.
Animal research only
- Improved T-cell counts and function in immunosuppressed patients
- Approved adjunct in chronic hepatitis B and C in multiple countries
- Studied as a vaccine adjuvant in older adults and in sepsis, where trials showed mortality signals worth further study
Mechanistically plausible
- Signals through Toll-like receptors on dendritic cells, promoting T-cell maturation and shifting the immune response toward effective pathogen clearance while dampening excessive inflammation.
Common internet claims
- Online discussion frequently presents Thymosin alpha-1 as a proven treatment rather than a research compound.
Not established
- Human efficacy for the outcomes commonly claimed
- Optimal route, quantity and duration in humans
- Long-term human safety
Evidence distribution
Each band is a live PubMed search for Thymosin alpha-1, filtered to that kind of study. Top is the strongest evidence; the base is reasoning, not proof. A band with no records means that kind of study has not been published for this compound yet.
Mechanism and reported findings
Signals through Toll-like receptors on dendritic cells, promoting T-cell maturation and shifting the immune response toward effective pathogen clearance while dampening excessive inflammation.
- Improved T-cell counts and function in immunosuppressed patients
- Approved adjunct in chronic hepatitis B and C in multiple countries
- Studied as a vaccine adjuvant in older adults and in sepsis, where trials showed mortality signals worth further study
- Used in oncology supportive care in some health systems
Strength of the evidence: Genuine randomised human trial data and regulatory approval outside the US; not FDA-approved for US marketing.
Safety and known cautions
Immune modulation is not risk-free in autoimmune disease or transplant recipients. Prescription medicine where approved.
Evidence at a glance
No single score, on purpose. The line beside each bar shows how much reported outcomes vary between studies.
Development stage
- Discovery
- Preclinical
- Phase 1
- Phase 2
- Phase 3Current
- Regulatory review
- Approved